Abstract | BACKGROUND: METHODS: This paper reports on a consecutive prospective study of patients with CNV secondary to PM who were treated with intravitreal bevacizumab (1.25 mg/0.05 ml). Patients underwent complete ophthalmic evaluation, which included best-corrected visual acuity testing measured with Early Treatment Diabetic Retinopathy Study charts, optical coherence tomography (OCT), and fluorescein angiography. RESULTS: There were 17 eyes of 17 patients, and the mean age was 55.4 (SD 10.0) years. At the 6-month follow-up, the mean visual acuity improved by 8.4 letters (p = 0.04). Forty-one per cent of patients increased at least one line, and 17% increased more than six lines. There were no cases of moderate vision loss (>or=3 lines) or severe vision loss (>or=6 lines). The mean OCT foveal thickness decreased by 79.6 mum (p = 0.002). Favourable outcomes were obtained in all subgroups. Patients received an average of one injection. As a complication, there was a tear of the retinal pigment epithelium. No other ocular or systemic side effects were observed. CONCLUSION: In our study, intravitreal bevacizumab appeared to be safe and efficacious in eyes with CNV secondary to PM.
|
Authors | L Arias, N Planas, S Prades, J M Caminal, M Rubio, O Pujol, G Roca |
Journal | The British journal of ophthalmology
(Br J Ophthalmol)
Vol. 92
Issue 8
Pg. 1035-9
(Aug 2008)
ISSN: 1468-2079 [Electronic] England |
PMID | 18653595
(Publication Type: Clinical Trial, Journal Article, Review)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Adult
- Aged
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Choroidal Neovascularization
(drug therapy, etiology, physiopathology)
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Myopia, Degenerative
(complications, physiopathology)
- Prospective Studies
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(drug effects)
|